LISTING OF THE CLAIMS

Claims 1-15 (Canceled).

Claim 16 (Currently Amended). An oral hydrophilic matrix formulation suitable for once-a-day administration to a patient comprising:

a) ~~a valproate compound~~ divalproex sodium, and;

b) said ~~valproate compound~~ divalproex sodium in admixture with a sufficient quantity of a pharmaceutically acceptable polymer, so that said formulation exhibits the following in-vitro dissolution profile, when measured in a type 2 dissolution apparatus (paddle) at 100 rpm, at a temperature of 37 ± 0.5°C, in 500 ml of 0.1N HCl for 45 minutes, followed by 900 ml of 0.05N phosphate buffer containing 75 mM sodium laurel sulfate, pH 5.5, for the remainder of the testing period:

   i. no more than about 30% of total valproate is released after 3 hours of measurement in said apparatus;

   ii. from about 40 to about 70% of total valproate is released after 9 hours of measurement in said apparatus;

   iii. from about 55 to about 95% of total valproate is released after 12 hour of measurement in said apparatus, and;

   iv. not less than 85% of total valproate is released after 18 hours of measurement in said apparatus.

Claims 17-19 (Canceled).